Quantum Genomics SA (PA:ALQGC) made a number of announcements when it presented its three-year strategic plan on 19 April 2018. Importantly, it is accelerating both its hypertension and heart failure programmes. The NEW-HOPE study in 250 hypertensive overweight patients is expected to complete patient dosing by the end of the year (previously Q119). It is also moving forward with the Phase IIb trial in heart failure without waiting for the final results due to the safety data seen so far and positive results in recent animal studies. The study is expected to launch in Q418 with results expected in H220.
NEW-HOPE enrolling faster than expected
In November, Quantum Genomics announced that it had recruited the first patients into the NEW-HOPE trial in 250 hypertensive overweight patients across 25 major US hospitals, with a primary endpoint of change from baseline in office systolic blood pressure (SBP) at week eight. Recruitment is outpacing internal projections and it now believes it can complete patient dosing by the end of 2018 (previously Q119). We now expect data in Q119 (previously H119).
To read the entire report Please click on the pdf File Below: